Trinity Biotech revenue up 16.4% to €19.7m
The Nasdaq and Irish Stock Exchange-quoted company, which develops and manufactures diagnostic products for the point-of-care and clinical laboratory markets, recorded a like-for-like increase in operating profits from $1.4m (€1.2m) to $2m (€1.6m) and a 23.5% growth in after-tax profits, over the same timeframe, from $1m (€800,000) to $1.2m (€957,000).
Rory Nealon, Trinity’s chief financial officer, said growth had been achieved in each of the company’s geographical markets. The company operates in Europe, North America, Asia and Africa.
